NetworkNewsBreaks — AREV Life Sciences Global Co
Post# of 16
(Total Views: 205)
Posted On: 04/22/2022 4:21:49 PM
NetworkNewsBreaks — AREV Life Sciences Global Corp. (CSE: AREV) (OTC: AREVF) to Conduct Key Research with TransBIOTech, Names New COO
AREV Life Sciences Global (CSE: AREV) (OTC: AREVF) has partnered with TransBIOTech, a publicly supported preclinical research organization, in a project to research cannabinoids and other early-stage commercial programs. TransBIOTech works with and is supported by the Canadian government through the Natural Sciences and Engineering Research Council (“NSERC”) in collaboration with the Canadian Institutes of Health Research (“CIHR”). AREV and TransBIOTech will work together to establish a foundation for further research focused on specific understandings of the company’s recent chemical entity development including initial toxicity, pharmacokinetics and metabolism modeling essential for human studies and eventual commercialization. In addition, AREV also named a new chief operating officer. The company noted that Kevin Phelps, CPA and AREV board member, will be assuming the responsibilities of company COO. Phelps brings 40 years of biotech and general business expertise to the new role. He has served in a variety of executive positions, including as CEO, CFO and vice president of business development.
“TransBIOTech is engaging with AREV in its initial research on cannabinoids and other early-stage commercial research programs,” said AREV CEO Mike Withrow in the press release. “Our agreement with TransBIOTech signals the initiation of a robust clinical initiative with numerous collaborators to facilitate data on some of the more promising phytomedicinal therapeutics currently relevant to today’s public health challenges. AREV Life Sciences is determined to enhance our scientific acumen by partnering with dynamic programs that will facilitate breakthrough discoveries of therapeutic innovation relevant to contemporary pandemic infectious disease and human nutrition. By leveraging our proprietary extraction technologies paired with the discovery capacities of TransBIOTech and other well-respected research institutions, we are laying the groundwork for initial animal studies to identify data sets that will satisfy regulatory authorities.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
AREV Life Sciences Global (CSE: AREV) (OTC: AREVF) has partnered with TransBIOTech, a publicly supported preclinical research organization, in a project to research cannabinoids and other early-stage commercial programs. TransBIOTech works with and is supported by the Canadian government through the Natural Sciences and Engineering Research Council (“NSERC”) in collaboration with the Canadian Institutes of Health Research (“CIHR”). AREV and TransBIOTech will work together to establish a foundation for further research focused on specific understandings of the company’s recent chemical entity development including initial toxicity, pharmacokinetics and metabolism modeling essential for human studies and eventual commercialization. In addition, AREV also named a new chief operating officer. The company noted that Kevin Phelps, CPA and AREV board member, will be assuming the responsibilities of company COO. Phelps brings 40 years of biotech and general business expertise to the new role. He has served in a variety of executive positions, including as CEO, CFO and vice president of business development.
“TransBIOTech is engaging with AREV in its initial research on cannabinoids and other early-stage commercial research programs,” said AREV CEO Mike Withrow in the press release. “Our agreement with TransBIOTech signals the initiation of a robust clinical initiative with numerous collaborators to facilitate data on some of the more promising phytomedicinal therapeutics currently relevant to today’s public health challenges. AREV Life Sciences is determined to enhance our scientific acumen by partnering with dynamic programs that will facilitate breakthrough discoveries of therapeutic innovation relevant to contemporary pandemic infectious disease and human nutrition. By leveraging our proprietary extraction technologies paired with the discovery capacities of TransBIOTech and other well-respected research institutions, we are laying the groundwork for initial animal studies to identify data sets that will satisfy regulatory authorities.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)